Mineralys Therapeutics, Inc. Common Stock (NASDAQ:MLYS) — Market Cap & Net Worth
Market Cap & Net Worth: Mineralys Therapeutics, Inc. Common Stock (MLYS)
Mineralys Therapeutics, Inc. Common Stock (NASDAQ:MLYS) has a market capitalization of $2.16 Billion ($2.16 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5985 globally and #1821 in its home market, demonstrating a 2.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mineralys Therapeutics, Inc. Common Stock's stock price $29.26 by its total outstanding shares 79139956 (79.14 Million). Analyse cash efficiency ratio of Mineralys Therapeutics, Inc. Common Stoc to see how efficiently the company converts income to cash.
Mineralys Therapeutics, Inc. Common Stock Market Cap History: 2023 to 2026
Mineralys Therapeutics, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows growth from $680.60 Million to $2.32 Billion (20.59% CAGR).
Index Memberships
Mineralys Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.09% | #144 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #649 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.13% | #92 of 263 |
Weight: Mineralys Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mineralys Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mineralys Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MLYS by Market Capitalization
Companies near Mineralys Therapeutics, Inc. Common Stock in the global market cap rankings as of May 2, 2026.
Key companies related to Mineralys Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Mineralys Therapeutics, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Mineralys Therapeutics, Inc. Common Stock's market cap moved from $680.60 Million to $ 2.32 Billion, with a yearly change of 20.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.32 Billion | -19.37% |
| 2025 | $2.87 Billion | +188.93% |
| 2024 | $994.00 Million | +46.05% |
| 2023 | $680.60 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Mineralys Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.16 Billion USD |
| MoneyControl | $2.16 Billion USD |
| MarketWatch | $2.16 Billion USD |
| marketcap.company | $2.16 Billion USD |
| Reuters | $2.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, … Read more